vs

Side-by-side financial comparison of Fortress Biotech, Inc. (FBIO) and TEJON RANCH CO (TRC). Click either name above to swap in a different company.

TEJON RANCH CO is the larger business by last-quarter revenue ($21.1M vs $16.1M, roughly 1.3× Fortress Biotech, Inc.). TEJON RANCH CO runs the higher net margin — 7.5% vs -24.5%, a 32.0% gap on every dollar of revenue. On growth, TEJON RANCH CO posted the faster year-over-year revenue change (17.7% vs 6.3%). Over the past eight quarters, TEJON RANCH CO's revenue compounded faster (68.8% CAGR vs 11.0%).

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

Tejon Ranch Company, based in Lebec, California, is one of the largest private landowners in California. The company was incorporated in 1936 to organize the ownership of a large tract of land that was consolidated from four Mexican land grants acquired in the 1850s and 1860s by ranch founder Edward Fitzgerald Beale.

FBIO vs TRC — Head-to-Head

Bigger by revenue
TRC
TRC
1.3× larger
TRC
$21.1M
$16.1M
FBIO
Growing faster (revenue YoY)
TRC
TRC
+11.4% gap
TRC
17.7%
6.3%
FBIO
Higher net margin
TRC
TRC
32.0% more per $
TRC
7.5%
-24.5%
FBIO
Faster 2-yr revenue CAGR
TRC
TRC
Annualised
TRC
68.8%
11.0%
FBIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FBIO
FBIO
TRC
TRC
Revenue
$16.1M
$21.1M
Net Profit
$-3.9M
$1.6M
Gross Margin
66.1%
30.6%
Operating Margin
-28.8%
10.9%
Net Margin
-24.5%
7.5%
Revenue YoY
6.3%
17.7%
Net Profit YoY
41.8%
-64.7%
EPS (diluted)
$-0.15
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBIO
FBIO
TRC
TRC
Q4 25
$16.1M
$21.1M
Q3 25
$17.6M
$12.0M
Q2 25
$16.4M
$8.3M
Q1 25
$13.1M
$8.2M
Q4 24
$15.1M
$17.9M
Q3 24
$14.6M
$10.9M
Q2 24
$14.9M
$5.7M
Q1 24
$13.0M
$7.4M
Net Profit
FBIO
FBIO
TRC
TRC
Q4 25
$-3.9M
$1.6M
Q3 25
$5.8M
$1.7M
Q2 25
$15.5M
$-1.7M
Q1 25
$-10.6M
$-1.5M
Q4 24
$-6.8M
$4.5M
Q3 24
$-12.9M
$-1.8M
Q2 24
$-10.9M
$957.0K
Q1 24
$-15.4M
$-914.0K
Gross Margin
FBIO
FBIO
TRC
TRC
Q4 25
66.1%
30.6%
Q3 25
67.4%
28.4%
Q2 25
69.9%
40.9%
Q1 25
63.5%
15.0%
Q4 24
69.1%
42.9%
Q3 24
69.4%
22.9%
Q2 24
61.6%
45.3%
Q1 24
53.9%
0.3%
Operating Margin
FBIO
FBIO
TRC
TRC
Q4 25
-28.8%
10.9%
Q3 25
-38.6%
-16.9%
Q2 25
-222.2%
-48.8%
Q1 25
-169.9%
-50.7%
Q4 24
-158.3%
11.9%
Q3 24
-151.0%
-34.9%
Q2 24
-186.5%
-62.4%
Q1 24
-280.6%
-53.8%
Net Margin
FBIO
FBIO
TRC
TRC
Q4 25
-24.5%
7.5%
Q3 25
33.2%
14.0%
Q2 25
94.4%
-20.6%
Q1 25
-80.6%
-17.8%
Q4 24
-44.7%
25.0%
Q3 24
-88.0%
-16.9%
Q2 24
-73.5%
16.8%
Q1 24
-118.3%
-12.3%
EPS (diluted)
FBIO
FBIO
TRC
TRC
Q4 25
$-0.15
$0.05
Q3 25
$0.11
$0.06
Q2 25
$0.45
$-0.06
Q1 25
$-0.48
$-0.05
Q4 24
$-0.16
$0.16
Q3 24
$-0.76
$-0.07
Q2 24
$-0.73
$0.04
Q1 24
$-1.04
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBIO
FBIO
TRC
TRC
Cash + ST InvestmentsLiquidity on hand
$79.4M
$9.5M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$49.9M
$475.2M
Total Assets
$185.5M
$630.5M
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBIO
FBIO
TRC
TRC
Q4 25
$79.4M
$9.5M
Q3 25
$86.2M
$3.6M
Q2 25
$74.4M
$2.5M
Q1 25
$91.3M
$12.3M
Q4 24
$57.3M
$39.3M
Q3 24
$58.9M
$27.4M
Q2 24
$76.2M
$33.0M
Q1 24
$83.8M
$35.6M
Total Debt
FBIO
FBIO
TRC
TRC
Q4 25
$52.4M
Q3 25
$47.8M
Q2 25
$50.0M
Q1 25
$56.4M
Q4 24
$58.0M
Q3 24
$52.5M
Q2 24
$67.0M
Q1 24
$61.4M
Stockholders' Equity
FBIO
FBIO
TRC
TRC
Q4 25
$49.9M
$475.2M
Q3 25
$55.9M
$473.2M
Q2 25
$43.9M
$471.5M
Q1 25
$22.3M
$472.5M
Q4 24
$22.7M
$473.6M
Q3 24
$21.2M
$468.3M
Q2 24
$17.9M
$469.2M
Q1 24
$23.0M
$467.4M
Total Assets
FBIO
FBIO
TRC
TRC
Q4 25
$185.5M
$630.5M
Q3 25
$181.4M
$629.6M
Q2 25
$159.9M
$618.5M
Q1 25
$178.1M
$614.6M
Q4 24
$144.2M
$608.0M
Q3 24
$127.1M
$598.0M
Q2 24
$145.7M
$590.8M
Q1 24
$164.6M
$581.6M
Debt / Equity
FBIO
FBIO
TRC
TRC
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×
Q1 24
2.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBIO
FBIO
TRC
TRC
Operating Cash FlowLast quarter
$-12.5M
$6.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
3.88×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBIO
FBIO
TRC
TRC
Q4 25
$-12.5M
$6.1M
Q3 25
$-6.1M
$-2.4M
Q2 25
$-27.6M
$-381.0K
Q1 25
$-19.6M
$-1.3M
Q4 24
$-12.9M
$14.3M
Q3 24
$-20.1M
$2.1M
Q2 24
$-21.8M
$-1.8M
Q1 24
$-25.4M
$777.0K
Free Cash Flow
FBIO
FBIO
TRC
TRC
Q4 25
Q3 25
$-14.6M
Q2 25
$-20.0M
Q1 25
$-18.9M
Q4 24
$-42.9M
Q3 24
$-16.8M
Q2 24
$-15.8M
Q1 24
$-7.3M
FCF Margin
FBIO
FBIO
TRC
TRC
Q4 25
Q3 25
-122.2%
Q2 25
-240.6%
Q1 25
-230.1%
Q4 24
-239.3%
Q3 24
-155.2%
Q2 24
-277.2%
Q1 24
-99.0%
Capex Intensity
FBIO
FBIO
TRC
TRC
Q4 25
Q3 25
102.3%
Q2 25
236.0%
Q1 25
213.7%
Q4 24
319.1%
Q3 24
0.0%
174.3%
Q2 24
245.5%
Q1 24
109.5%
Cash Conversion
FBIO
FBIO
TRC
TRC
Q4 25
3.88×
Q3 25
-1.04×
-1.43×
Q2 25
-1.78×
Q1 25
Q4 24
3.19×
Q3 24
Q2 24
-1.88×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons